156779-10-1

Basic information

• Product Name: Methyl 1-Benzyl-2-oxo-1,2,3,4-tetrahydropyridine-5-carboxylate
• Synonyms: Methyl 1-Benzyl-2-oxo-1,2,3,4-tetrahydropyridine-5-carboxylate;Methyl 1-benzyl-6-oxo-1,4,5,6-tetrahydropyridine-3-carboxylate
• CAS NO: 156779-10-1
• Molecular Formula: C₁₄H₁₅NO₃
• Molecular Weight: 245.2738
• Mol File: 156779-10-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Methyl 1-Benzyl-2-oxo-1,2,3,4-tetrahydropyridine-5-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 1-Benzyl-2-oxo-1,2,3,4-tetrahydropyridine-5-carboxylate(156779-10-1)
• EPA Substance Registry System: Methyl 1-Benzyl-2-oxo-1,2,3,4-tetrahydropyridine-5-carboxylate(156779-10-1)

Safety Data

• Hazardous Substances Data: 156779-10-1(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
Methyl 1-Benzyl-2-oxo-1,2,3,4-tetrahydropyridine-5-carboxylate is used as a building block in organic synthesis for the creation of other chemical compounds. Its unique structure and properties make it a versatile component in the synthesis of various organic molecules.
Used in Drug Discovery:
Methyl 1-Benzyl-2-oxo-1,2,3,4-tetrahydropyridine-5-carboxylate is used as a valuable tool in drug discovery. Its potential applications in the development of new pharmaceuticals make it an important compound for researchers working in the field of medicinal chemistry.
Used in Pharmaceutical Development:
Methyl 1-Benzyl-2-oxo-1,2,3,4-tetrahydropyridine-5-carboxylate is used in the development of new pharmaceuticals. Its unique properties and potential uses contribute to the advancement of drug development, offering new possibilities for the treatment of various diseases and conditions.

Upstream product

• 814-68-6 acryloyl chloride 
• 14376-92-2 (E/Z)-methyl 3-(benzylamino)acrylate 
• 100-46-9 benzylamine 
• 922-67-8 propynoic acid methyl ester 

Downstream Products

• 1427319-48-9 3-(((tert-butoxycarbonyl)amino)methyl)cyclobutanecarboxylic acid 
• 1352925-67-7 3-benzyl-3-azabicyclo[3.1.1]heptane 
• 487002-97-1 5-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]-2-oxo-1-piperidinecarboxylic acid 1,1-dimethylethyl ester 
• 487002-99-3 5-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]-5,6-dihydro-2-oxo-1(2H)-pyridinecarboxylic acid 1,1-dimethylethyl ester 
• 919537-30-7 5-[[(1,1-dimethylethyl)diphenylsilyloxy]methyl]-2-piperidinone 
• 146059-77-0 5-(hydroxymethyl)piperidin-2-one 
• 744212-58-6 1-benzyl-5-(bromomethyl)piperidin-2-one 
• 890936-71-7 (3S)-1-benzyl-6-oxopiperidine-3-carboxylic acid 

Relevant articles and documents

ARYL, HETEROARY, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS

Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, Formula IV, and Formula V, or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.

ANGIOTENSIN-(1-7) ANALOGS AND METHODS RELATING THERETO

Angiotensin (1-7) analogs are provided. The analogs contain one or more substitutions with non-natural amino acid cis-3-(aminomethyl)cyclobutanecarboxylic acid (ACCA). Also provided are methods of making such analogs and methods for using such analogs as

Synthesis of a conformationally constrained δ-amino acid building block

Conformationally restricted amino acids are important components in peptidomimetics and drug design. Herein, we describe the synthesis of a novel, non-proteinogenic constrained delta amino acid containing a cyclobutane ring, cis-3(aminomethyl)cyclobutane

A short synthesis of (±)-cytisine

The synthesis of racemic cytisine 1 has been completed using (i) N-selective alkylation of 6-bromopyridone with bromide 6 and (ii) Pd(o) mediated intramolecular a-arylation of lactam 8 as key steps to achieve rapid assembly of the tricyclic core skeleton of the lupin alkaloids.

Construction of Hydroxylated Alkaloids (+/-)-Mannonolactam, (+/-)-Deoxymannojirimycin, and (+/-)-Prosopinine through Aza-Annulation

The aza-annulation of β-enamino carbonyl substrates with acrylate derivatives provides an efficient and convenient route for the regioselective construction of δ-lactams.This two-step ring-forming sequence involved initial generation of the benzyl enamine through either a condensation or conjugate addition reaction with BnNH2, followed by aza-annulation with acryloyl chloride or acrylic anhydride.Controlled by the rigid framework of the intermediate lactam, introduction of ring substituents was accomplished with high relative stereoselectivity.The carbonyl functionality, which was necessary to direct the regioselectivity of the aza-annulation reaction, was then transformed into a protected hydroxyl substituent through Baeyer-Villiger oxidation.The resultant δ-lactam product was used as a valuable intermediate in the synthesis of three natural products.Subsequent modification of this δ-lactam gave the naturally occurring α-mannosidase inhibitors (+/-)-mannonolactam and (+/-)-deoxymannojirimycin, while synthesis of the alkaloid (+/-)-prosopinine was accomplished through homologation of the lactam carbonyl.